RC48 has garnered approval for its effective application in the treatment of cancer patients with HER2-overexpressing (IHC2+/3+) locally advanced or metastatic gastric carcinoma/gastric and gastroesophageal junction carcinoma (GC/GEJC) as well as urothelial carcinoma (UC) who have been treated with systemic chemotherapy agents at least twice (12). Here, ERBB2 is linked to cancer.